Literature DB >> 24508801

Secreted phospholipases A₂are differentially expressed and epigenetically silenced in human breast cancer cells.

Vesna Brglez1, Anja Pucer1, Jože Pungerčar1, Gérard Lambeau2, Toni Petan3.   

Abstract

Secreted phospholipases A2 (sPLA2s) have recently been associated with several cancers, but their role in breast cancer is unknown. Here we demonstrate that mRNA expression of group IIA, III and X sPLA2s differs both in vivo in tumour biopsies and in breast cancer cells in vitro. Their expression is differentially regulated by DNA methylation and histone acetylation and, significantly, all three genes are silenced in aggressive triple negative cells due to both mechanisms. The transcription start site promoter region and the upstream CpG islands, exclusive to the group X sPLA2 gene, have variable roles in the regulation of sPLA2 expression. Our results suggest that the differential expression of hGIIA, hGIII and hGX sPLA2s in breast cancer cells is a consequence of various degrees of epigenetic silencing due to DNA hypermethylation and histone deacetylation.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Breast cancer; DNA methylation; Epigenetics; Histone acetylation; Lipid signalling; Secreted phospholipase A(2)

Mesh:

Substances:

Year:  2014        PMID: 24508801     DOI: 10.1016/j.bbrc.2014.01.182

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  12 in total

Review 1.  Phospholipase Signaling in Breast Cancer.

Authors:  Yu Jin Lee; Kyeong Jin Shin; Hyun-Jun Jang; Dong-Young Noh; Sung Ho Ryu; Pann-Ghill Suh
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Epigenetic control of group V phospholipase A2 expression in human malignant cells.

Authors:  Mario Menschikowski; Albert Hagelgans; Brit Nacke; Carsten Jandeck; Olga A Mareninova; Liana Asatryan; Gabriele Siegert
Journal:  Tumour Biol       Date:  2015-12-29

Review 3.  New targeted therapies for breast cancer: A focus on tumor microenvironmental signals and chemoresistant breast cancers.

Authors:  Armel Hervé Nwabo Kamdje; Paul Faustin Seke Etet; Lorella Vecchio; Richard Simo Tagne; Jeremie Mbo Amvene; Jean-Marc Muller; Mauro Krampera; Kiven Erique Lukong
Journal:  World J Clin Cases       Date:  2014-12-16       Impact factor: 1.337

4.  Differential expression of lipid metabolism-related proteins in different breast cancer subtypes.

Authors:  Sewha Kim; YuKyung Lee; Ja Seung Koo
Journal:  PLoS One       Date:  2015-03-09       Impact factor: 3.240

5.  Primary cilium suppression by SREBP1c involves distortion of vesicular trafficking by PLA2G3.

Authors:  Hannah Laura Gijs; Nicolas Willemarck; Frank Vanderhoydonc; Niamat Ali Khan; Jonas Dehairs; Rita Derua; Etienne Waelkens; Yoshitaka Taketomi; Makoto Murakami; Patrizia Agostinis; Wim Annaert; Johannes V Swinnen
Journal:  Mol Biol Cell       Date:  2015-04-22       Impact factor: 4.138

6.  LncRNAs as new biomarkers to differentiate triple negative breast cancer from non-triple negative breast cancer.

Authors:  Mingming Lv; Pengfei Xu; Ying Wu; Lei Huang; Wenqu Li; Shanshan Lv; Xiaowei Wu; Xin Zeng; Rong Shen; Xuemei Jia; Yongmei Yin; Yun Gu; Hongyan Yuan; Hui Xie; Ziyi Fu
Journal:  Oncotarget       Date:  2016-03-15

Review 7.  Key Players in Choline Metabolic Reprograming in Triple-Negative Breast Cancer.

Authors:  Egidio Iorio; Maria José Caramujo; Serena Cecchetti; Francesca Spadaro; Giulia Carpinelli; Rossella Canese; Franca Podo
Journal:  Front Oncol       Date:  2016-09-30       Impact factor: 6.244

8.  Multiplatform Investigation of Plasma and Tissue Lipid Signatures of Breast Cancer Using Mass Spectrometry Tools.

Authors:  Alex Ap Rosini Silva; Marcella R Cardoso; Luciana Montes Rezende; John Q Lin; Fernando Guimaraes; Geisilene R Paiva Silva; Michael Murgu; Denise Gonçalves Priolli; Marcos N Eberlin; Alessandra Tata; Livia S Eberlin; Sophie F M Derchain; Andreia M Porcari
Journal:  Int J Mol Sci       Date:  2020-05-20       Impact factor: 5.923

9.  Antitumoral effects of γCdcPLI, a PLA2 inhibitor from Crotalus durissus collilineatus via PI3K/Akt pathway on MDA-MB-231 breast cancer cell.

Authors:  Sarah N C Gimenes; Daiana S Lopes; Patrícia T Alves; Fernanda V P V Azevedo; Lara Vecchi; Luiz R Goulart; Thais C S Rodrigues; André L Q Santos; Vera L de C Brites; Thaise L Teixeira; Cláudio V da Silva; Matheus H Dias; Samuel C Teixeira; Renata S Rodrigues; Kelly A G Yoneyama; Ricardo A Oliveira; Veridiana de M Rodrigues
Journal:  Sci Rep       Date:  2017-08-01       Impact factor: 4.379

Review 10.  Structural and Functional Aspects of Targeting the Secreted Human Group IIA Phospholipase A2.

Authors:  Ryung Rae Kim; Zheng Chen; Timothy J Mann; Karine Bastard; Kieran F Scott; W Bret Church
Journal:  Molecules       Date:  2020-09-28       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.